- Company
- Rise of 4-drug combos in hypertension/hyperlipidemia Tx mkt
- by Kim, Jin-Gu Aug 3, 2023 05:35am
- The growth of 3-drug combinations has slowed down in the hypertension/hyperlipidemia combination drug market. After recording double-digit YoY growth every quarter until the first half of last year, the spurt has slowed sharply since the end of last year. On the other hand, the 4-drug combinations that newly entered the market are rapidly exp
- Company
- Rx of Generics for Xarelto doubled in 1 yr
- by Kim, Jin-Gu Aug 2, 2023 05:25am
- Generics for Xarelto (Rivaroxaban) are rapidly increasing their prescription performance. In the first half of last year, prescription sales of 8 billion won were recorded, more than doubling in one year. On the other hand, the original product's prescription performance decreased by half during the same period. Generics for Xarelto, 3.9 b
- Company
- Why HK Inno.N’s sales and operating profit fell
- by Kim, Jin-Gu Aug 2, 2023 05:25am
- HK Inno.N's sales and operating profit declined significantly in Q2 this year. This can be attributed to the sharp decline in MSD vaccine sales amid brisk earnings of its flagship product, K-Cab (tegoprazan),. HK InnoN explained that shipments of Gardasil, its cervical cancer vaccine, were concentrated in the second quarter of last year b
- Company
- GC Biopharma ends its 2-quarter deficit run
- by Kim, Jin-Gu Aug 2, 2023 05:25am
- GC Biopharma, which had recorded an operating loss for 2 consecutive quarters, succeeded in turning a profit this quarter. GC Biopharma explained that the company has succeeded in doing so by increasing sales of highly profitable products and efficient execution of costs. GC Biopharma also announced plans to accelerate its overseas busine
- Company
- Inrebic, tx for myelofibrosis, has become available in Big5
- by Eo, Yun-Ho Aug 2, 2023 05:25am
- Inrebic, a new drug for myelofibrosis, has settled down in Big 5. According to related industries, Korea BMS Pharmaceutical's myelofibrosis treatment Inrebic passed the Drug Committee (DC) of the big five medical institutions, including SMC, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical Center, and Severance Hos
- Company
- Shaperon files Phase II IND for its AD treatment
- by Lee, Seok-Jun Aug 1, 2023 05:33am
- On the 31st, Sharperon announced that it had submitted an investigational new drug (IND) application to the US Food and Drug Administration to conduct a Phase II trial in the U.S. for its atopic dermatitis treatment, ‘NuGel.’ The company plans to evaluate the pharmacokinetics, safety, tolerance, and efficacy of NuGel through the multin
- Company
- US FDA starts review of GC Biopharma’s Alyglo
- by Kim, Jin-Gu Aug 1, 2023 05:33am
- GC Biopharma announced on July 31st that its drug, 'GC5107B (immunoglobulin 10% for intravenous administration) is being reviewed in earnest by the U.S. Food and Drug Administration. GC5107B is one of GC Biopharma’s blood derivative products that goes by the brand name Alyglo. The company had submitted a Biologics License Application (
- Company
- Pediatric neurofibroma new drug Koselugo will be reimbursed
- by Eo, Yun-Ho Aug 1, 2023 05:33am
- Attention is focusing on whether progress will be made in discussing the insurance coverage of Koselugo, a new drug for pediatric neurofibroma. According to the industry, AstraZeneca's neurofibromatosis new drug Koselugo will be submitted to the HIRA Pharmaceutical Reimbursement Evaluation Committee. As it recently submitted additional suppl
- Company
- Will Hanmi be able to develop its own Saxenda for Koreans?
- by Kim, Jin-Gu Aug 1, 2023 05:33am
- Hanmi Pharm has decided to change the development direction for its GLP-1 class drug ‘efpeglenatide.’ Instead of developing it as a diabetes treatment as before, the company plans to develop the drug as an obesity treatment. The industry’s attention was focused on the Global Phase III trial that Sanofi and Hanmi Pharm had conducted wit
- Company
- Equipped with two new drugs this year alone
- by Jul 31, 2023 05:28am
- Janssen challenges with a new mechanism, BMS widening the gap with maintenance therapy Janssen has added a new drug for multiple myeloma in Korea. This is the second permit this year. It is noteworthy whether Janssen will change the multiple myeloma market where BMS dominates with Celgene. On the 26th, the Ministry of Food and Drug Safety ap
